5,6-MDO-MiPT
From Wikipedia, the free encyclopedia
| Clinical data | |
|---|---|
| Other names | 5,6-Methylenedioxy-N-methyl-N-isopropyltryptamine |
| Routes of administration | Oral[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | Unknown[1] |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H20N2O2 |
| Molar mass | 260.337 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
5,6-MDO-MiPT, or 5,6-methylenedioxy-N-methyl-N-isopropyltryptamine, is a lesser-known chemical compound of the tryptamine family.[1] It is the 5,6-methylenedioxy derivative of methylisopropyltryptamine (MiPT) and an analogue of 5-MeO-MiPT.[1] In his 1991 book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin lists the dose range as greater than 50 mg orally and its duration as unknown.[1] The drug produced few to no effects, with effects including parasthesia and lightheadedness, at doses of up to 75 mg orally.[1] Its chemical synthesis has been described.[1] 5,6-MDO-MiPT was first described in the scientific literature by 1982.[2]